000 -LEADER | |
---|---|
fixed length control field | 04972cam a2200229 4500 |
001 - CONTROL NUMBER | |
control field | NMDX6643 |
008 - FIXED-LENGTH DATA ELEMENTS--GENERAL INFORMATION | |
fixed length control field | 120401t2010 xxu||||| |||| 00| 0 eng d |
022 ## - INTERNATIONAL STANDARD SERIAL NUMBER | |
International Standard Serial Number | 14644096 |
100 ## - MAIN ENTRY--PERSONAL NAME | |
Personal name | Yoong, W. |
240 ## - UNIFORM TITLE | |
Uniform title | <a href="BJU international.">BJU international.</a> |
245 ## - TITLE STATEMENT | |
Title | Neuromodulative treatment with percutaneous tibial nerve stimulation for intractable detrusor instability:outcomes following a shortened 6-week protocol. |
260 ## - PUBLICATION, DISTRIBUTION, ETC. (IMPRINT) | |
Date of publication, distribution, etc. | 2010 |
500 ## - GENERAL NOTE | |
General note | NMUH Staff Publications |
500 ## - GENERAL NOTE | |
General note | Available in print at Ferriman Library |
500 ## - GENERAL NOTE | |
General note | 106 |
520 ## - SUMMARY, ETC. | |
Summary, etc. | <p style="margin: 0px 0px 0.5em; line-height: 17.999801635742188px;"><span style="font-size: 8pt;"><strong>OBJECTIVE:</strong> To describe our initial outcome data&nbsp;<span class="highlight">following</span>&nbsp;a&nbsp;<span class="highlight">shortened</span>&nbsp;<span class="highlight">6-week</span>&nbsp;<span class="highlight">treatment</span>&nbsp;<span class="highlight">protocol</span>&nbsp;with&nbsp;<span class="highlight">percutaneous</span>&nbsp;<span class="highlight">tibial</span><span class="highlight">nerve</span>&nbsp;<span class="highlight">stimulation</span>&nbsp;(PTNS) in women with overactive bladder syndrome (OABS) unresponsive to bladder retraining and anticholinergic therapy.</span></p><h4 style="margin: 0px 0.25em 0px 0px; text-transform: uppercase; float: left; line-height: 17.999801635742188px;"><span style="font-size: 8pt;">PATIENTS AND METHODS:</span></h4><p style="margin: 0px 0px 0.5em; line-height: 17.999801635742188px;"><span style="font-size: 8pt;">This was a prospective observational study over a 6-month period. In all, 43 women with OABS refractory to medical therapy were treated with a&nbsp;<span class="highlight">shortened</span>&nbsp;PTNS&nbsp;<span class="highlight">protocol</span>&nbsp;that consisted of 6 weekly 30 min sessions. Bladder symptom diaries and health-related quality of life (HRQL) assessed using the short-form seven-item self-report. Incontinence Impact Questionnaire (IIQ-7) were completed before and after&nbsp;<span class="highlight">treatment</span>. A positive response was defined as: (i) OAB symptoms no longer being bothersome; (ii) reduction by half in frequency episodes and (iii) reduction by 25% in IIQ-7<span class="highlight">outcomes</span>.</span></p><h4 style="margin: 0px 0.25em 0px 0px; text-transform: uppercase; float: left; line-height: 17.999801635742188px;"><span style="font-size: 8pt;">RESULTS:</span></h4><p style="margin: 0px 0px 0.5em; line-height: 17.999801635742188px;"><span style="font-size: 8pt;">All 43 women (median age 55.3 years) completed six treatments with a positive response rate of 69.7%. In the positive responders, the median daytime and nocturnal frequency was reduced by half after 6 weeks of&nbsp;<span class="highlight">treatment</span>&nbsp;(11.8 vs 6.9 and 3.5 vs 1.8, respectively, P &lt; 0.05) and the patients reported fewer urge leak episodes per 24 h (median 3.5 vs 2.4, P &lt; 0.05). The median IIQ-7 scores improved by 25% (30.4 vs 24.3, P &lt; 0.05) in responders, while the median number of pads changed in 24 h also decreased by 34% (3.8 vs 2.5, P &lt; 0.05). The median acceptability of the technique when scored by Visual Analogue Score was 9.6/10 and no side-effects were reported.</span></p><h4 style="margin: 0px 0.25em 0px 0px; text-transform: uppercase; float: left; line-height: 17.999801635742188px;"><span style="font-size: 8pt;">CONCLUSION:</span></h4><p style="margin: 0px 0px 0.5em; line-height: 17.999801635742188px;"><span style="font-size: 8pt;">A&nbsp;<span class="highlight">shortened</span>&nbsp;<span class="highlight">6-week</span>&nbsp;<span class="highlight">treatment</span>&nbsp;with PTNS appears to be successful, with a significant reduction in symptoms and improvement in HRQL. This early data suggest that the duration of&nbsp;<span class="highlight">treatment</span>&nbsp;for peripheral neuromodulation can be halved compared with the conventional 12 weeks, which would make it more acceptable and cost effective for patients. A randomised controlled trial of 6 weeks vs 12 weeks of PTNS therapy would be useful in determining the optimal duration of&nbsp;<span class="highlight">treatment</span></span></p> |
700 ## - ADDED ENTRY--PERSONAL NAME | |
Personal name | Ridout, A.E. |
700 ## - ADDED ENTRY--PERSONAL NAME | |
Personal name | Damodaram, M. |
700 ## - ADDED ENTRY--PERSONAL NAME | |
Personal name | Dadswell, R. |
856 ## - ELECTRONIC LOCATION AND ACCESS | |
Uniform Resource Identifier | <a href="http://www.ncbi.nlm.nih.gov/pubmed/20590544">http://www.ncbi.nlm.nih.gov/pubmed/20590544</a> |
856 ## - ELECTRONIC LOCATION AND ACCESS | |
Uniform Resource Identifier | <a href="http://onlinelibrary.wiley.com/doi/10.1111/j.1464-410X.2010.09461.x/epdf">http://onlinelibrary.wiley.com/doi/10.1111/j.1464-410X.2010.09461.x/epdf</a> |
Withdrawn status | Lost status | Damaged status | Not for loan | Collection code | Home library | Current library | Shelving location | Date acquired | Total Checkouts | Date last seen | Price effective from | Koha item type |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Staff publications for NMDX | Ferriman Information and Library Service (North Middlesex) | Ferriman Information and Library Service (North Middlesex) | Online | 07/06/2022 | 07/06/2022 | 07/06/2022 | UNKNOWN |